Viracta Therapeutics (VIRX) Short Interest Ratio & Short Volume

Short interest is the volume of Viracta Therapeutics shares that have been sold short but have not yet been closed out or covered. As of December 31st, investors have sold 609,900 shares of VIRX short. 2.18% of Viracta Therapeutics' shares are currently sold short. Learn More on Viracta Therapeutics' current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 2.18% of Viracta Therapeutics' floating shares are currently sold short.

Viracta Therapeutics saw a decline in short interest during the month of December. As of December 31st, there was short interest totaling 609,900 shares, a decline of 79.7% from the previous total of 3,000,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Viracta Therapeutics currently has issued a total of 39,740,000 shares. Some of Viracta Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Viracta Therapeutics currently has a public float of 28,010,000 shares.

2.18% of Viracta Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Viracta Therapeutics: Citius Pharmaceuticals, Inc. (7.51%), Lakeshore Biopharma Co., Ltd. (0.72%), Longeveron Inc. (15.01%), Natural Alternatives International, Inc. (0.09%), DURECT Co. (3.05%), Cardio Diagnostics Holdings, Inc. (4.19%), Alterity Therapeutics Limited (1.98%), LAVA Therapeutics (0.32%), CytoMed Therapeutics Limited (1.70%), Equillium, Inc. (0.59%),

As of the most recent reporting period, the following stocks had the largest short interest positions: AppLovin Co. ($5.83 billion), Charter Communications, Inc. ($3.77 billion), Reddit, Inc. ($2.98 billion), The Kroger Co. ($2.97 billion), International Paper ($2.64 billion), SoFi Technologies, Inc. ($1.99 billion), Rivian Automotive, Inc. ($1.93 billion), Onsemi ($1.81 billion), SoundHound AI, Inc. ($1.59 billion), and Moderna, Inc. ($1.57 billion). View all of the most shorted stocks.

Short selling VIRX is an investing strategy that aims to generate trading profit from Viracta Therapeutics as its price is falling. VIRX shares are trading down $0.01 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Viracta Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of VIRX, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including VIRX, twice per month. The most recent reporting period available is December, 31 2024.